Companies: 10,795·Total market cap: $144.5T
Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited

TEVANYSEHealthcare● Active
$34.19
$-0.24(-0.70%)
Market Cap$39.8B
P/E Ratio—
52W High$37.35
52W Low$14.99
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Teva Pharmaceutical Industries Limited (TEVA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0000818686 · TEVA · NYSE · as of Jun 8, 2026

Filing snapshot

1,000+
Total Filings
144
Latest Form
2026-06-05
Most Recent
1982
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0000818686 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-03
Fiscal Year End
Feb 3, 2026
Accession No.
0001193125-26-034532
Primary Document
d93612d10k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0000818686 · Accession 0001193125-26-034532

Latest Key Filings

6-KQuarterly Report
LIVE FILING
2017-12-27
View 6-K on SEC
8-KCurrent Report
8-K
2026-05-28Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-05-28
View
10-QQuarterly Report
10-Q
2026-04-29
View
8-KCurrent Report
FORM 8-K
2026-04-29
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-03-31
View
ARSARS
ARS
2026-03-31
View
DEF 14AProxy Statement
DEF 14A
2026-03-31
View
3Initial Statement of Beneficial Ownership
3
2026-02-23
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-09
View
10-KAnnual Report
10-K
2026-02-03
View
8-KCurrent Report
FORM 8-K
2026-01-28
View
8-KCurrent Report
FORM 8-K
2026-01-12
View
8-KCurrent Report
8-K
2025-12-11
View
10-QQuarterly Report
10-Q
2025-11-05
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-11-05
View
Showing 1–15 of 362 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0000818686  |  Exchange: NYSE · Healthcare

Teva Pharmaceutical Industries Limited (NYSE: TEVA) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 1982. As a Healthcare sector company with CIK 0000818686, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Teva Pharmaceutical Industries Limited's most comprehensive regulatory disclosure. The most recent Teva Pharmaceutical Industries Limited 10-K was filed on 2026-02-03 for fiscal year ending 2026. Historical TEVA 10-K annual reports are available from 2017 through 2026.

Investors researching Teva Pharmaceutical Industries Limited SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
NTRA SEC Filings →BIIB SEC Filings →DXCM SEC Filings →PHG SEC Filings →WAT SEC Filings →BNTX SEC Filings →LH SEC Filings →STE SEC Filings →
→ TEVA Financials→ TEVA Earnings→ TEVA Insider Trades

Frequently Asked Questions

TEVA SEC Filings · 8 questions

Teva Pharmaceutical Industries Limited (TEVA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. Teva Pharmaceutical Industries Limited's CIK is 0000818686.

TEVA SEC filingsTeva Pharmaceutical Industries Limited SEC documentsfind TEVA 10-K